Research Article Open Access

Monitoring Of Blood L-DOPA And L-DOPA Metabolite Concentrations And Adverse Events In Patients With Advanced Parkinsons Disease Receiving L-DOPA And Amantadine Combination Therapy: A Clinical Study

Abstract

As L-DOPA replacement is the main treatment for patients with Parkinson’s disease, monitoring of the blood dopamine (DA) concentration is useful for prediction of peripheral adverse events. We studied patients with advanced Parkinson’s disease for whom L-DOPA and an NMDA receptor antagonist, amantadine, had been prescribed since 2006 at Sakura Hospital, Toho University Medical Center. The blood concentrations of L-DOPA, DA, 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-O-methyldopa (3-OMD) before and at 1, 2 and 3 hours after administration of L-DOPA and amantadine were measured using a high-performance liquid chromatography-electrochemical detector (HPLC-ECD) system. We used hospital medical records to establish the age of the patients, and their gender, Unified Parkinson’s Disease Rating Scale (UPDRS) motor scores, L-DOPA dosing regime, use of amantadine in combination with L-DOPA, and adverse events.

Mitsutoshi Satoh*, Ami Kuzuu, Hirokazu Doi, Toru Masaka, Ryuji Sakakibara

To read the full article Download Full Article | Visit Full Article